185 related articles for article (PubMed ID: 36229595)
1. JAK/BCL2 inhibition acts synergistically with LSD1 inhibitors to selectively target ETP-ALL.
Benyoucef A; Haigh K; Cuddihy A; Haigh JJ
Leukemia; 2022 Dec; 36(12):2802-2816. PubMed ID: 36229595
[TBL] [Abstract][Full Text] [Related]
2. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
Delgado-Martin C; Meyer LK; Huang BJ; Shimano KA; Zinter MS; Nguyen JV; Smith GA; Taunton J; Winter SS; Roderick JR; Kelliher MA; Horton TM; Wood BL; Teachey DT; Hermiston ML
Leukemia; 2017 Dec; 31(12):2568-2576. PubMed ID: 28484265
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.
Maude SL; Dolai S; Delgado-Martin C; Vincent T; Robbins A; Selvanathan A; Ryan T; Hall J; Wood AC; Tasian SK; Hunger SP; Loh ML; Mullighan CG; Wood BL; Hermiston ML; Grupp SA; Lock RB; Teachey DT
Blood; 2015 Mar; 125(11):1759-67. PubMed ID: 25645356
[TBL] [Abstract][Full Text] [Related]
4. BCL2 Inhibitor (ABT-737): A Restorer of Prednisolone Sensitivity in Early T-Cell Precursor-Acute Lymphoblastic Leukemia with High MEF2C Expression?
Kawashima-Goto S; Imamura T; Tomoyasu C; Yano M; Yoshida H; Fujiki A; Tamura S; Osone S; Ishida H; Morimoto A; Kuroda H; Hosoi H
PLoS One; 2015; 10(7):e0132926. PubMed ID: 26172269
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential.
Treanor LM; Zhou S; Janke L; Churchman ML; Ma Z; Lu T; Chen SC; Mullighan CG; Sorrentino BP
J Exp Med; 2014 Apr; 211(4):701-13. PubMed ID: 24687960
[TBL] [Abstract][Full Text] [Related]
6. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199.
Chonghaile TN; Roderick JE; Glenfield C; Ryan J; Sallan SE; Silverman LB; Loh ML; Hunger SP; Wood B; DeAngelo DJ; Stone R; Harris M; Gutierrez A; Kelliher MA; Letai A
Cancer Discov; 2014 Sep; 4(9):1074-87. PubMed ID: 24994123
[TBL] [Abstract][Full Text] [Related]
7. ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling.
Goossens S; Radaelli E; Blanchet O; Durinck K; Van der Meulen J; Peirs S; Taghon T; Tremblay CS; Costa M; Farhang Ghahremani M; De Medts J; Bartunkova S; Haigh K; Schwab C; Farla N; Pieters T; Matthijssens F; Van Roy N; Best JA; Deswarte K; Bogaert P; Carmichael C; Rickard A; Suryani S; Bracken LS; Alserihi R; Canté-Barrett K; Haenebalcke L; Clappier E; Rondou P; Slowicka K; Huylebroeck D; Goldrath AW; Janzen V; McCormack MP; Lock RB; Curtis DJ; Harrison C; Berx G; Speleman F; Meijerink JP; Soulier J; Van Vlierberghe P; Haigh JJ
Nat Commun; 2015 Jan; 6():5794. PubMed ID: 25565005
[TBL] [Abstract][Full Text] [Related]
8. STAT5 activation promotes progression and chemotherapy resistance in early T-cell precursor acute lymphoblastic leukemia.
Tremblay CS; Saw J; Boyle JA; Haigh K; Litalien V; McCalmont H; Evans K; Lock RB; Jane SM; Haigh JJ; Curtis DJ
Blood; 2023 Jul; 142(3):274-289. PubMed ID: 36989489
[TBL] [Abstract][Full Text] [Related]
9. Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells.
Haydn T; Metzger E; Schuele R; Fulda S
Cell Death Dis; 2017 Jun; 8(6):e2879. PubMed ID: 28617441
[TBL] [Abstract][Full Text] [Related]
10. The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.
Girardi T; Vereecke S; Sulima SO; Khan Y; Fancello L; Briggs JW; Schwab C; de Beeck JO; Verbeeck J; Royaert J; Geerdens E; Vicente C; Bornschein S; Harrison CJ; Meijerink JP; Cools J; Dinman JD; Kampen KR; De Keersmaecker K
Leukemia; 2018 Mar; 32(3):809-819. PubMed ID: 28744013
[TBL] [Abstract][Full Text] [Related]
11. IL7R overexpression in adult acute lymphoblastic leukemia is associated to JAK/STAT pathway mutations and identifies patients who could benefit from targeted therapies.
Gianfelici V; Messina M; Paoloni F; Peragine N; Lauretti A; Fedullo AL; Di Giacomo F; Vignetti M; Vitale A; Guarini A; Chiaretti S; Foà R
Leuk Lymphoma; 2019 Mar; 60(3):829-832. PubMed ID: 30188230
[No Abstract] [Full Text] [Related]
12. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
Peirs S; Frismantas V; Matthijssens F; Van Loocke W; Pieters T; Vandamme N; Lintermans B; Dobay MP; Berx G; Poppe B; Goossens S; Bornhauser BC; Bourquin JP; Van Vlierberghe P
Leukemia; 2017 Oct; 31(10):2037-2047. PubMed ID: 28074072
[TBL] [Abstract][Full Text] [Related]
13. IL-15 regulates Bcl-2 family members Bim and Mcl-1 through JAK/STAT and PI3K/AKT pathways in T cells.
Shenoy AR; Kirschnek S; Häcker G
Eur J Immunol; 2014 Aug; 44(8):2500-7. PubMed ID: 24825007
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia.
Braun TP; Coblentz C; Curtiss BM; Coleman DJ; Schonrock Z; Carratt SA; Callahan RL; Maniaci B; Druker BJ; Maxson JE
Proc Natl Acad Sci U S A; 2020 Jun; 117(24):13670-13679. PubMed ID: 32471953
[TBL] [Abstract][Full Text] [Related]
15. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
[TBL] [Abstract][Full Text] [Related]
16. Clinical features and prognosis of pediatric acute lymphocytic leukemia with JAK-STAT pathway genetic abnormalities: a case series.
Hu M; Liu R; Li J; Zhang L; Cao J; Yue M; Zhong D; Tang R
Ann Hematol; 2023 Sep; 102(9):2445-2457. PubMed ID: 37209119
[TBL] [Abstract][Full Text] [Related]
17. HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia.
Akahane K; Sanda T; Mansour MR; Radimerski T; DeAngelo DJ; Weinstock DM; Look AT
Leukemia; 2016 Jan; 30(1):219-28. PubMed ID: 26265185
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic ZEB2 activation drives sensitivity toward KDM1A inhibition in T-cell acute lymphoblastic leukemia.
Goossens S; Peirs S; Van Loocke W; Wang J; Takawy M; Matthijssens F; Sonderegger SE; Haigh K; Nguyen T; Vandamme N; Costa M; Carmichael C; Van Nieuwerburgh F; Deforce D; Kleifeld O; Curtis DJ; Berx G; Van Vlierberghe P; Haigh JJ
Blood; 2017 Feb; 129(8):981-990. PubMed ID: 28069602
[TBL] [Abstract][Full Text] [Related]
19. Eradication of Central Nervous System Leukemia of T-Cell Origin with a Brain-Permeable LSD1 Inhibitor.
Saito S; Kikuchi J; Koyama D; Sato S; Koyama H; Osada N; Kuroda Y; Akahane K; Inukai T; Umehara T; Furukawa Y
Clin Cancer Res; 2019 Mar; 25(5):1601-1611. PubMed ID: 30518632
[TBL] [Abstract][Full Text] [Related]
20. Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia.
Tavakoli Shirazi P; Eadie LN; Page EC; Heatley SL; Bruning JB; White DL
Cancer Lett; 2021 Aug; 512():28-37. PubMed ID: 33971281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
